Loss to follow-up of adults in public HIV care systems in central mozambique: Identifying obstacles to treatment

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 3, 2009, Pages 397-405

  Micek, Mark A ^a,b   Gimbel Sherr, Kenneth ^a,b   Baptista, Alberto João ^c   Matediana, Eduardo ^c   Montoya, Pablo ^a,b   Pfeiffer, James ^a,b   Melo, Armando ^d   Gimbel Sherr, Sarah ^a,b   Johnson, Wendy ^a,b   Gloyd, Stephen ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HEALTH ALLIANCE INTERNATIONAL   (United States)

^c Mozambique Ministry of Health   (Mozambique)

^d Mozambique Ministry of Health   (Mozambique)

Author keywords

HIV care utilization; HIV treatment; Loss to follow up; Resource limited settings

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MOZAMBIQUE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; MOZAMBIQUE; NATIONAL HEALTH PROGRAMS; PATIENT COMPLIANCE;

EID: 70350521738     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ab73e2     Document Type: Article

References (44)

1. WHO/UNAIDS/UNICEF. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report. 2008. Geneva, Switzerland: World Health Organization 2008.
2. National ART Data for December 2008. Mozambique Ministry of Health; 2009. Available at: http://www.misau.gov/mz/pt/hiv-sida/programa- de-tratamento-antiretroviral-tarv/dados-tarv-nacionais. Accessed April 1, 2009.
3. Mozambique National AIDS Council. Universal Declaration of Commitment on HIV and AIDS: Mozambique Progress Report for the United Nations GeneralAssembly Special Session on HIVand AIDS, 2006-2007. Maputo, Mozambique: Mozambique National AIDS Council 2008.
4. Hutchinson PL, Mahlalela X. Utilization of voluntary counseling and testing services in the Eastern Cape South Africa. AIDS Care 2006, 18:446-455.
5. Sherr L, Lopman B, Kakowa M, et al. Voluntary counselling and testing: uptake, impact on sexual behaviour, and HIV incidence in a rural Zimbabwean cohort. AIDS. 2007;21:851-860.
6. Temmerman M, Quaghebeur A, Mwanyumba F, et al. Mother-to-child HIV transmission in resource poor settings: how to improve coverage? AIDS. 2003;17:1239-1242.
7. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007; 4:e298.
8. Giordano TP, Suarez-Almazor ME, Grimes RM. The population effectiveness of highly active antiretroviral therapy: are good drugs good enough? Curr HIV/AIDS Rep. 2005;2:177-183.
9. National Directorate of Medical Care, National STD/HIV/AIDS Control Program, Mozambique Ministry of Health: HIV Epidemiological SurveillanceRound, 2007. Maputo, Mozambique; 2008.
10. Janssen RS, Holtgrave DR, Valdiserri RO, et al. The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals. Am J Public Health. 2001;91:1019-1024.
11. WHO. Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach, 2003 Revision. Geneva, Switzerland: World Health Organization; 2004.
12. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121.
13. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immuno-logic response. California Collaborative Treatment Group. AIDS. 1999; 13:1099-1107.
14. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
15. Press N, Tyndall MW, Wood E, et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S112-S117.
16. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
17. Fairley CK, Permana A, Read TR. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med. 2005;6:366-369.
18. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 28:47-58.
19. Walsh JC, Horne R, Dalton M, et al. Reasons for non-adherence to antiretroviral therapy: patients' perspectives provide evidence of multiple causes. AIDS Care. 2001;13:709-720.
20. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23: 360-361.
21. Kalichman SC, Simbayi LC. HIV testing attitudes, AIDS stigma, and voluntary HIV counselling and testing in a black township in Cape Town, South Africa. Sex Transm Infect. 2003;79:442-447.
22. Fortenberry JD, McFarlane M, Bleakley A, et al. Relationships of stigma and shame to gonorrhea and HIV screening. Am J Public Health. 2002;92: 378-381.
23. UNICEF. Evaluation of United Nations-Supported Pilot Projects for the Prevention of Mother-to-Child Transmission of HIV. New York, NY: United Nations Children's Fund (UNICEF); 2003.
24. Dabis F, Ekpini ER. HIV-1/AIDS and maternal and child health in Africa. Lancet. 2002;359:2097-2104.
25. Malonza IM, Richardson BA, Kreiss JK, et al. The effect of rapid HIV-1 testing on uptake of perinatal HIV-1 interventions: a randomized clinical trial. AIDS. 2003;17:113-118.
26. Perez F, Mukotekwa T, Miller A, et al. Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience. Trop Med Int Health. 2004;9:774-783. (Pubitemid 38962004)
27. Painter TM, Diaby KL, Matia DM, et al. Women's reasons for not participating in follow up visits before starting short course antiretroviral prophylaxis for prevention of mother to child transmission of HIV: qualitative interview study. BMJ. 2004;329:543.
28. Bwirire LD, Fitzgerald M, Zachariah R, et al. Reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi. Trans R Soc Trop Med Hyg. 2008; 102:1195-1200.
29. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS. 2003;17(Suppl 3):S5-S15.
30. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006; 296:782-793.
31. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43:770-776.
32. Sackoff JE, McFarland JW, Shin SS. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. J Acquir Immune Defic Syndr. 2000;23:178-183.
33. Landon BE, Wilson IB, McInnes K, et al. Physician specialization and the quality of care for human immunodeficiency virus infection. Arch Intern Med. 2005;165:1133-1139.
34. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res. 2000;35:389-416.
35. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005; 38:96-103.
36. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-549.
37. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15:1707-1715.
38. Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37:1270-1281.
39. Giordano TP, White AC Jr, Sajja P, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr. 2003;32:399-405.
40. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544-546.
41. Griffin SJ. Lost to follow-up: the problem of defaulters from diabetes clinics. Diabet Med. 1998;15(Suppl 3):S14-S24.
42. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296:679-690.
43. Stubbs B, Micek MA, Pfeiffer J, et al. Understanding the effect of the treatment partner program on adherence to HAART in central Mozambique. 2008. In press.
44. Gimbel-Sherr K, Micek MA, Pfeiffer J, et al. Task shifting to mid-level clinical health providers: an evaluation of quality of ART provided by tecnicos de medicina and physicians in Mozambique. Paper presented at: XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.